Pulmatrix (2PU) Stock Price & Analysis
2PU Stock Chart & Stats
- Day’s Range
- EUR 1.12 - EUR 1.12
- 52-Week Range
- EUR 0.87 - EUR 4.12
- Previous Close
- EUR 1.15
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 4.58M
- Enterprise Value
- EUR 4.31M
- Total Cash (Recent Filing)
- EUR 2.17M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.87
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
No Reported Debt
The absence of reported debt reduces interest expense and refinancing pressure, giving Pulmatrix greater flexibility than a similarly loss-making company with leverage. This supports preservation of scarce cash and may help management direct funding toward clinical development and strategic execution.
Improving Cash Burn
The substantial reduction in operating cash outflow indicates better cost control and a lower rate of cash consumption than in earlier periods. Although Pulmatrix remains cash-flow negative, sustained improvement could extend its funding runway and reduce the urgency of external financing.
Merger Execution Support
Shareholder approval removes an important execution hurdle for the planned combination and enables the corporate actions needed to proceed. If completed, the transaction could broaden Pulmatrix’s strategic platform and provide a path beyond its currently limited standalone operating base.
Bears Say
No Current Revenue Base
With effectively no current revenue, Pulmatrix lacks internally generated commercial support for research, operations, or future investment. Its ability to create durable value therefore remains dependent on successful development, partnering, or commercialization of candidates rather than an established sales base.
Persistent Cash Consumption
Ongoing negative operating and free cash flow means the business continues to consume cash while generating little or no revenue. This creates continuing dependence on financing or transactions to fund operations, and leaves less resilience if development timelines extend or commercialization is delayed.
Dilution And Capital Restructuring
The approved merger measures could materially reshape ownership and the capital structure through new share issuance and a larger authorized share pool. Such changes may dilute existing holders and increase reliance on transaction success to offset the consequences of a weakened standalone equity base.
Pulmatrix News
2PU FAQ
What was Pulmatrix’s price range in the past 12 months?
What is Pulmatrix’s market cap?
When is Pulmatrix’s upcoming earnings report date?
How were Pulmatrix’s earnings last quarter?
Is Pulmatrix overvalued?
Does Pulmatrix pay dividends?
What is Pulmatrix’s EPS estimate?
How many shares outstanding does Pulmatrix have?
What happened to Pulmatrix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pulmatrix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Pulmatrix
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter Ludlum
- Employees
- 2
- Website
- www.pulmatrix.com
- Address
- 945 Concord Street, Framingham, MA, 01701, US
Pulmatrix (2PU) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |
